Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: VLAD who wrote (8667)	5/29/1998 3:29:00 AM
From: Zebra 365	Read Replies (3) \| Respond to of 23519

Here's an old press release on ICOS. Much more of a threat to PFE than to VVUS but only just started the phase II studies. Remember, any drug as popular as Viagra can be engineered around the patent but, because Viagra is now available, no other oral ED drug will get expedited review from the FDA. This means that you can plan on at least a year from New Drug Application to market for any of these new oral drugs. Meanwhile VVUS is testing the new Prasosin-Alprostdil mix for use in the MUSE system. Reports of higher effectiveness are promising but no data is published. ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~' ICOS Announces Initiation of Overseas Phase 2 Trial With IC351 BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 13, 1998--ICOS Corporation (NASDAQ:ICOS - news) announced today the initiation of a Phase 2 clinical trial with IC351 in patients with male erectile dysfunction (MED). This randomized placebo-controlled, crossover study is being performed overseas. The Phase 2 clinical trial includes patients with mild to moderate MED. The study is designed to assess the safety and physiological effects of IC351 in this patient population. Approximately 20-30 million men in the United States are estimated to suffer from some degree of MED. This condition, sometimes referred to as impotence, can be a consequence of several factors, among them cardiovascular insufficiency. IC351 is a selective PDE5 phosphodiesterase inhibitor that is thought to reinforce the normal physiological signals to increase blood flow. Such an increase in blood flow is an integral part of the erectile response. The Company's goal is to demonstrate that IC351 is a useful treatment for MED and cardiovascular disorders. ICOS is discovering and developing new pharmaceuticals by seeking points of intervention in the inflammatory process that may lead to specific and efficacious drugs. ICOS' research and drug development programs involve both acute and chronic conditions such as ARDS, acute pancreatitis, asthma, hemorrhagic shock, male erectile dysfunction, multiple sclerosis, myocardial infarction, and psoriasis. >>> Zebra

To: VLAD who wrote (8667)	5/29/1998 8:21:00 AM
From: E'Lane	Read Replies (1) \| Respond to of 23519

<<sed to use apomorphine in my practice to make dogs vomit.>> You had to practice making dogs vomit??? GROOOOSSSS! Sorry VLAD...couldn't resiist! <g> GOOOOOD MORNING VVUSERS! Yo pal with a smile! (if you say it just right, it kinda rhymes..cute, huh?) E'Lane

To: VLAD who wrote (8667)	5/29/1998 8:38:00 AM
From: DaiS	Respond to of 23519

Vlad, During my coffee break I followed your altercation with Dale Russel re the AUA meeting abstracts. I agree that he is biased against muse. In the VA study, apart from the points you make, 84% were frightened of needles, and 25 out of the 107 did not respond to injections, hardly good candidates for muse!! In the muse vs caverject study there were no differences when the higher muse dose was used. And at the lower dose the difference 8:14 in the numbers opting for muse:caverject is not statistically significant. In the study in the urology practice setting the dropout from 27% to 18%, the "Most disappointing..." conclusion is nowhere near significant given N=115. N>300 would be required. This latter study seems the most powerful negative one at the meeting and I don't agree that the scales are on the negative side for muse overall. The Nexmed and MCHM abstracts are a joke - to think nexmed went up 80% in one day DaiS

To: VLAD who wrote (8667)	5/29/1998 9:09:00 AM
From: E'Lane	Respond to of 23519

Did anyone catch Oprah yesterday. I didn't and was curious if anyone else did. Would like to know (considering her MAD COW experience) what kind of light she shed on the ED subject. Have been wondering if she taped it BEFORE or AFTER the Viagra deaths. An update would be appreciated...Thanks in advance! E'Lane don't ya just love how Viagra shows as a non-word in the edit window on SI??? Too funny! It's not even a recognized word in the English language!!!